Antibodies recognizing α-synuclein
US10669331B2 · kind B2 · utility
2Cited by
23References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 16, 2019 |
| Grant date | Jun 2, 2020 |
| Priority date | — |
| Expiry date | Apr 16, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/6896
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of α-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with α-synuclein, particularly accumulation of α-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.